CyGenica
CyGenica is a biotech company focused on revolutionizing intracellular therapeutic development through a non-viral, non-toxic platform for safe and targeted molecular delivery. Their mission is to improve patient outcomes worldwide by developing highly specific and selective intracellular delivery of therapeutics, including nucleotides and proteins, to specific cell types. They aim to offer safe and affordable treatment solutions for diseases such as cancer and cystic fibrosis, enhancing the quality of life for patients. Their innovative GEENIE platform enables highly specific cell-membrane translocation of drugs, reducing dosage and toxicity, and making targeted therapy more effective and safer.
Industries
Nr. of Employees
small (1-50)
CyGenica
700 NIP, NCL Innovation Park, Dr. Homi Bhabha Road, Pashan, Pune – 411 008, Maharashtra, India
Patents
Products
Engineered intracellular delivery platform (cell-membrane translocating biomolecule)
A proprietary engineered biomolecule platform that enables non-endocytic translocation of molecular cargos into cells to improve intracellular delivery efficiency and reduce required dose.
Formulation for delivery of gene-editing machinery
Delivery formulation and methods to transport CRISPR/Cas components into target cells with improved delivery rates compared to existing approaches.
Non-toxic live-cell labelling reagent
A live-cell staining reagent that crosses membranes without damaging cells and labels ~90% of cells within one hour; available in targeted variants for specific intracellular compartments (e.g., nucleus, mitochondria).
Engineered intracellular delivery platform (cell-membrane translocating biomolecule)
A proprietary engineered biomolecule platform that enables non-endocytic translocation of molecular cargos into cells to improve intracellular delivery efficiency and reduce required dose.
Formulation for delivery of gene-editing machinery
Delivery formulation and methods to transport CRISPR/Cas components into target cells with improved delivery rates compared to existing approaches.
Non-toxic live-cell labelling reagent
A live-cell staining reagent that crosses membranes without damaging cells and labels ~90% of cells within one hour; available in targeted variants for specific intracellular compartments (e.g., nucleus, mitochondria).
Services
Collaborative agreements for licensing or co-development of intracellular delivery platforms and conjugates, including investor and grant-supported projects.
Support for candidate selection, lead optimization, preclinical studies and regulatory submission planning toward IND and first-in-human trials.
Collaborative agreements for licensing or co-development of intracellular delivery platforms and conjugates, including investor and grant-supported projects.
Support for candidate selection, lead optimization, preclinical studies and regulatory submission planning toward IND and first-in-human trials.
Expertise Areas
- Intracellular drug delivery
- Oncology-targeted therapeutics (glioblastoma, HER2+ breast cancer)
- Delivery of nucleic acid therapeutics and gene-editing cargos
- Preclinical development and IND-enabling studies
Key Technologies
- Engineered cell-penetrating biomolecules
- Non-endocytic membrane translocation
- Nucleic acid therapeutics delivery (siRNA, ASO, mRNA)
- CRISPR/Cas delivery systems
News & Updates
CyGenica at Intracellular Drug Delivery Summit 2023
Presentation on achieving therapeutic localization with selective delivery to intracellular targets.
CyGenica at BIO ASIA 2023
Participation in the event to explore partnership opportunities.
CEO Dr Nusrat J M Sanghamitra at BIO 2023
Attending the BIO 2023 International Convention in Boston.
USFDA Orphan Drug Designation for Glioblastoma Treatment
CyGenica's limited secures USFDA approval for orphan drug designation.
The company was featured at GLOBALGOALSCAST, highlighting its innovative work.
CyGenica was featured in biopharmadealmakers in September 2021.
CyGenica at Intracellular Drug Delivery Summit 2023
Presentation on achieving therapeutic localization with selective delivery to intracellular targets.
CyGenica at BIO ASIA 2023
Participation in the event to explore partnership opportunities.
CEO Dr Nusrat J M Sanghamitra at BIO 2023
Attending the BIO 2023 International Convention in Boston.
USFDA Orphan Drug Designation for Glioblastoma Treatment
CyGenica's limited secures USFDA approval for orphan drug designation.
The company was featured at GLOBALGOALSCAST, highlighting its innovative work.
CyGenica was featured in biopharmadealmakers in September 2021.